Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maine PBM Law Clears Hurdle; Magistrate Judge Recommends Lifting Injunction

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the decision would allow implementation of law requiring PBM transparency of rebates and other financial arrangements. Magistrate judge says law would not automatically result in regulatory "taking" of trade secrets. PCMA will seek full review by the district court.

You may also be interested in...



PCMA Will Appeal Court Decision Upholding Maine’s PBM Transparency Law

Bangor, Maine federal court adopts magistrate judge’s recommendation that preliminary injunction against Maine law be overturned. PCMA is seeking to block the law based on federal preemption under ERISA and a violation of the Takings Clause of the U.S. Constitution.

PCMA Will Appeal Court Decision Upholding Maine’s PBM Transparency Law

Bangor, Maine federal court adopts magistrate judge’s recommendation that preliminary injunction against Maine law be overturned. PCMA is seeking to block the law based on federal preemption under ERISA and a violation of the Takings Clause of the U.S. Constitution.

Maine Rx Not Required To Seek HHS Approval At This Time, Court Says

PhRMA's request that the state be required to seek HHS clearance of its drug discount program is denied. Judge says the unimplemented program is not "ripe" for review and PhRMA may reassert its challenge if Maine attempts to use the prior authorization provisions in its program.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel